Project Page

Back to search results
Research Centre DCRC Early Diagnosis and Prevention
Partner Institution Mental Health Research Institute
Project Description

Current means for the definitive diagnosis of Alzheimer's disease (AD) is dependent upon post-mortem examination of the brain for evidence of the disease's characteristic neuropathology.

With advances in research into interventions for AD, in terms of both medical treatments and lifestyle changes, the development of a reliable method of risk stratification is needed.

Advances in cerebral amyloid imaging as well as cerebral spinal fluid biomarker assays show promise; however, these tests are either of a high degree of invasiveness or impractical for use in the wider community. Thus there is an urgent need for less invasive alternatives, which are easily applied to the wider community.

Pending approval of use of PATH and AIBL sample by the respective Governance Committees ,this research program proposes to identify and assess biomarkers in biological samples from two large well-characterised cohorts, namely the Australian Imaging, Biomarker and Lifestyle (AIBL) study and the Canberra Personality and Total Health (PATH) study.

Our strategy will utilise three parallel streams of investigation, first, a targeted stream to evaluate candidate biomarkers in blood products, second, a discovery stream to identify novel biomarkers of AD and, third, a development stream to assess the suitability of multiplexing candidate biomarkers.

This will provide proof of concept towards the future development of assays for AD diagnostic, prediction and/or monitoring purposes.

Project Portfolio

Back to search results